Focused On-demand Library for Chromodomain-helicase-DNA-binding protein 1-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q86WJ1

UPID:

CHD1L_HUMAN

Alternative names:

Amplified in liver cancer protein 1

Alternative UPACC:

Q86WJ1; A5YM64; B4DDE1; B5MDZ7; Q53EZ3; Q5VXX7; Q6DD94; Q6PK83; Q86XH3; Q96HF7; Q96SP3; Q9BVJ1; Q9NVV8

Background:

Chromodomain-helicase-DNA-binding protein 1-like, also known as Amplified in liver cancer protein 1, plays a crucial role in DNA repair. It acts as an ATP-dependent chromatin remodeler, facilitating chromatin restructuring post-DNA damage. This protein is adept at recognizing and binding to poly-ADP-ribosylated histones, a key step in the DNA damage response, thereby activating its chromatin remodeler activity to promote efficient DNA repair.

Therapeutic significance:

Understanding the role of Chromodomain-helicase-DNA-binding protein 1-like could open doors to potential therapeutic strategies. Its pivotal function in DNA repair mechanisms positions it as a target for developing treatments aimed at enhancing the DNA damage response in diseases characterized by genomic instability.